

Table SI. PD-L1<sup>+</sup> neutrophils in blood of mice.

Time-point, h	Sham, %	CLP, %	P-value
24	2.647±1.117	4.433±0.77	0.085
48	3.867±1.22	9.583±2.222	0.017
72	7.003±0.512	16.3±3.716	0.013
96	4.387±2.531	12.933±1.877	0.009

Data are presented as the mean ± SD. PD-L1, programmed death ligand-1; CLP, cecal ligation and puncture.

Table SII. PD-L1<sup>+</sup> neutrophils in bone marrow of mice.

Time-point, h	Sham, %	CLP, %	P-value
24	6.197±1.127	10.867±0.493	0.003
48	5.197±2.05	14.7±1.353	0.003
72	9.797±1.928	25.367±6.037	0.013
96	9.417±2.029	17.433±2.616	0.014

Data are presented as the mean ± SD. PD-L1, programmed death ligand-1; CLP, cecal ligation and puncture.

Table SIII. Endotoxin levels in the blood of mice.

## A, 24 h time-point

Sham, EU/ml	CLP, EU/ml	Atezolizumab, EU/ml
0.272	0.373	0.509
0.152	0.399	0.576
0.149	0.567	0.416
0.336	0.584	0.472
0.21	0.559	0.411

## B, 48 h time-point

Sham, EU/ml	CLP, EU/ml	Atezolizumab, EU/ml
0.372	0.921	0.3
0.287	0.627	0.62
0.116	0.843	0.635
0.334	0.548	0.493
0.095	0.772	0.391

## C, 72 h time-point

Sham, EU/ml	CLP, EU/ml	Atezolizumab, EU/ml
0.262	0.959	0.495
0.137	0.975	0.628
0.245	0.959	0.759
0.204	0.714	0.487
0.305	1.172	0.45

CLP, cecal ligation and puncture.

Table SIV. Concentration of FD40S in the blood of mice.

## A, 24 h time-point

Sham, $\mu\text{g}/\text{ml}$	CLP, $\mu\text{g}/\text{ml}$	Atezolizumab, $\mu\text{g}/\text{ml}$
2.191	9.132	6.385
2.465	12.635	7.877
1.375	6.12	9.729
1.672	10.146	11.962
1.066	6.56	6.644

## B, 48 h time-point

Sham, $\mu\text{g}/\text{ml}$	CLP, $\mu\text{g}/\text{ml}$	Atezolizumab, $\mu\text{g}/\text{ml}$
1.747	18.859	13.454
3.49	24.85	19.389
2.779	27.171	8.245
3.006	28.287	13.288
2.766	25.955	11.126

## C, 72 h time-point

Sham, $\mu\text{g}/\text{ml}$	CLP, $\mu\text{g}/\text{ml}$	Atezolizumab, $\mu\text{g}/\text{ml}$
2.189	28.797	16.427
2.731	32.982	23.547
4.071	35.203	17.289
5.712	28.57	17.289
2.663	35.862	15.354

CLP, cecal ligation and puncture.

Table SV. Ileum histopathology scores of mice according to Chiu's score.

Sham	CLP	Atezolizumab
0	3	2
1	4	1
0	3	3
2	2	1
0	3	2
1	5	4
1	5	3
2	3	2

CLP, cecal ligation and puncture.

Table SVI. Tight junction protein expression in the ileum of mice.

Protein	Sham	CLP	Atezolizumab
Claudin-1	1.03±0.061	0.652±0.17 <sup>b</sup>	0.846±0.127 <sup>c</sup>
Occludin	1.02±0.125	0.68±0.194 <sup>b</sup>	0.888±0.194 <sup>c</sup>
ZO-1	1.01±0.137	0.794±0.124 <sup>a</sup>	0.896±0.092

<sup>a</sup>P<0.05, <sup>b</sup>P<0.01 vs. sham; <sup>c</sup>P<0.05 vs. CLP. CLP, cecal ligation and puncture; ZO-1, zonula occludens-1.

Table SVII. T lymphocyte apoptosis after co-culture *in vitro*.

Sham, %	CLP, %	Atezolizumab, %
7.5	27.4	12.5
7	27.5	11
7	24.8	12.2
10.5	31.7	16

CLP, cecal ligation and puncture.

Table SVIII. Survival time of mice post-operation during 144 h of observation.

CLP, h	Atezolizumab, h
122	136
104	100
52	144
112	112
98	Not dead
88	62
96	123
70	76
84	45
80	93
35	105
91	106

CLP, cecal ligation and puncture.